Skip to main content
Clinical Trials/NCT05671367
NCT05671367
Completed
Not Applicable

Evaluation of the Correlation Between Coronary Microvascular Resistance Based on Quantitative Flow Ratio and Major Adverse Cardiovascular Events in Patients With Obstructive Hypertrophic Cardiomyopathy: A Retrospective Cohort Study

China National Center for Cardiovascular Diseases1 site in 1 country340 target enrollmentStarted: January 1, 2017Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
China National Center for Cardiovascular Diseases
Enrollment
340
Locations
1
Primary Endpoint
The Major Adverse Cardiovascular Events related to HoCM

Overview

Brief Summary

About 60% of patients with hypertrophic cardiomyopathy have microvascular dysfunction. Microvascular dysfunction is directly related to prognosis in hypertrophic cardiomyopathy. This new measurement method is microcirculation resistance (MR) based on quantitative flow ratio (QFR), which does not need a pressure guide wire on the basis of angiography. The QFR system is used to evaluate the blood vessels distal pressure and blood flow, and their ratio is microcirculation resistance (MR). The quantitative blood flow fraction measurement system was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). This study is a single-center retrospective cohort study. Participants were selected from patients who were diagnosed with hypertrophic obstructive cardiomyopathy in Fuwai Hospital from January 2020 to November 2021. The risk factor is whether there is microcirculation resistance disorder. The outcome was the major adverse cardiovascular events related to HCM (including all-cause death, heart transplantation, left ventricular pacemaker, and heart failure readmission) that were followed up one year after angiography. Aim To further clarify whether there is a certain correlation between microvascular resistance and adverse cardiovascular prognosis.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The Major Adverse Cardiovascular Events related to HoCM

Time Frame: One-year followed up after angiography

including all-cause death, heart transplantation, left ventricular pacemaker, heart failure readmission

Secondary Outcomes

  • Borg Index after 6MWT(One-year followed up after angiography)
  • Scale of KCCQ-12(One-year followed up after angiography)

Investigators

Sponsor
China National Center for Cardiovascular Diseases
Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Lihong Ma

Director of Department of Traditional Chinese Medicine, Principal Investigator, Clinical Professor

China National Center for Cardiovascular Diseases

Study Sites (1)

Loading locations...

Similar Trials